Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cartin-Ceba, Rodrigo
ARREST, NCT04193878: ARrest RESpiraTory Failure From PNEUMONIA	Recruiting	3	600	US	Inhaled budesonide and formoterol, Pulmicort Respules (budesonide) and Perforomist (formoterol), Inhaled placebo, aerosolized 0.9% saline	Stanford University, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)	Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia	07/25	08/25
VIRUS, NCT04323787: Viral Infection and Respiratory Illness Universal Study[]: COVID-19 Registry	Recruiting	N/A	100000	US	observational, No Intervention	Mayo Clinic, Society of Critical Care Medicine, Boston University	Coronavirus	03/25	03/25
NCT06184308: Improving Outcomes in PICS With Home-Based Program of Rehabilitation and Health Coaching	Recruiting	N/A	220	US	Home-based Physical Rehabilitation, Health Coaching	Mayo Clinic	Post-Intensive Care Syndrome	07/26	07/26
Bime, Christian
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia	Terminated	3	409	Europe, US, RoW	Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo	Dompé Farmaceutici S.p.A	Infectious Pneumonia, Severe COVID-19	09/24	09/24
ARREST, NCT04193878: ARrest RESpiraTory Failure From PNEUMONIA	Recruiting	3	600	US	Inhaled budesonide and formoterol, Pulmicort Respules (budesonide) and Perforomist (formoterol), Inhaled placebo, aerosolized 0.9% saline	Stanford University, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)	Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia	07/25	08/25
NCT05938036: Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS	Recruiting	2	90	US	ALT-100 mAb, ALT-100 (Placebo)	Aqualung Therapeutics Corp.	Acute Respiratory Distress Syndrome (ARDS)	06/25	08/25